# US 2021/0275536 A1 · Appetite suppressant compositions and methods thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275536 A1
- Document ID: US20210275536A1
- Status: Published application
- Kind: A1
- Application number: 16/808,084
- Filed: 2020-03-03
- Published: 2021-09-09
- Earliest claimed: 2020-03-03
- Assignees: Red Mountain Holdings, LLC
- Applicants: Red Mountain Holdings, LLC
- Inventors: Suzanne Bentz
- Web page: https://patentgrep.com/patent/US20210275536A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 47/38: Cellulose; Derivatives thereof
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In various embodiments an appetite suppressant composition comprises at least one anorectic active ingredient (AAI); at least one of a nutritive substance, a controlled drug delivery agent (CDRA), and a cofactor; and optionally, an excipient. The AIA may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The CDRA may comprise a cellulosic. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.

## Claims

### Claim 1

An appetite suppressant composition comprising: at least one anorectic active ingredient; at least one of a nutritive substance, a controlled drug delivery agent, and a cofactor; and optionally, an excipient.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the anorectic active ingredient is selected from the group consisting of diethylpropion, amphetamine, benfluorex, bupropion, butanolide, caffeine, cathine, cetilistat, clobenzorex, D-fenfluramine, racemic-fenfluramine, ephedrine, etilamfetamine, exenatide, FG-7142 (diazepine inverse agonist), higenamine, liraglutide, lorcaserin, mazindol, mefenorex, metformin, methamphetamine, naltrexone, nicotine, orlistat, phenmetrazine, phendimetrazine, phentermine, phenylpropanolamine, pramlinatide, pseudoephedrine, pyroglutamyl-histidyl-glycine, rimonabant, semaglutide, sibutramine, topiramate, yohimbine, pro-drugs thereof, pharmaceutically acceptable salts thereof, and mixtures thereof.

### Claim 3 (depends on 1)

A pharmaceutical dosage form for oral administration comprising: a capsule; and the composition of claim 1 enclosed therein.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the nutritive substance is selected from the group consisting of a dried Spirulina algal species biomass powder, a dried Chlorella algal species biomass powder, a hydrolyzed powdered bovine or fish collagen, a bovine or porcine gelatin powder, egg albumin powder, calcium caseinate powder, powdered milk protein concentrate, whey protein isolate powder, yellow pea protein isolate, and mixtures thereof.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the controlled drug release agent is selected from the group consisting of agar, agarose, albumin, alginate, casein, chitin, chondroitin, dextrin, fibroin, fucoidan, galactan, gellan, guar, scleroglucan, pullulan, xyloglucan, pectin, xanthan, psyllium, silica gel, fumed silica, magnesium aluminum silicate, clay, bentonite, hectorite, mesoporous silica, cellulose, cellulose acetate, hyaluronan, elastin-like polypeptides, β-cyclodextrin, collagen, gelatin, chitosan, carrageenan, polylactic acid, polyglycolic acid, poly(lactic-glycolic acid) (PLGA), poly(2-hydroxyethyl methacrylate), poly(2-hydroxypropyl methacrylate), poly(acrylic acid), carboxymethyl cellulose, carboxyethyl cellulose, hydroxyethyl cellulose, hydrophobically-modified hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose, microcrystalline cellulose, nitrocellulose, polyvinyl alcohol, polyvinylpyrrolidone, polyvinylmethacrylate, carboxyvinyl polymers, polyvinylacetate, polyvinyl co-polymers, starch, modified starches, and mixtures thereof.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the cofactor is selected from the group consisting of calcium acetate, calcium ascorbate, calcium citrate, calcium gluconate, calcium nicotinate, calcium picolinate, chromium acetate, chromium ascorbate, chromium citrate, chromium gluconate, chromium nicotinate, chromium picolinate, copper acetate, copper ascorbate, copper citrate, copper gluconate, copper nicotinate, copper picolinate, magnesium acetate, magnesium ascorbate, magnesium citrate, magnesium gluconate, magnesium nicotinate, magnesium picolinate, manganese acetate, manganese ascorbate, manganese citrate, manganese gluconate, manganese nicotinate, manganese picolinate, potassium acetate, potassium ascorbate, potassium citrate, potassium gluconate, potassium nicotinate, potassium picolinate, selenium acetate, selenium ascorbate, selenium citrate, selenium gluconate, selenium nicotinate, selenium picolinate, zinc acetate, zinc ascorbate, zinc citrate, zinc gluconate, zinc nicotinate, zinc picolinate, and mixtures thereof.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the anorectic active ingredient comprises phentermine, phendimetrazine, or diethylpropion, the nutritive substance comprises a protein source, the controlled drug release agent comprises a cellulosic, and the cofactor comprises calcium picolinate, chromium picolinate, copper picolinate, magnesium picolinate, manganese picolinate, selenium picolinate, or zinc picolinate.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the cellulosic is hydroxypropyl methyl cellulose.

### Claim 9 (depends on 7)

The composition of claim 7, wherein the protein source is hydrolyzed powdered bovine or fish collagen.

### Claim 10 (depends on 7)

The composition of claim 7, wherein the cofactor is chromium picolinate.

### Claim 11

A method of suppressing appetite in an individual, the method comprising orally administering to the individual in need thereof a therapeutically effective amount of an appetite suppressant composition comprising at least one anorectic active ingredient; at least one of a nutritive substance, a controlled drug delivery agent, and a cofactor; and optionally, an excipient, wherein the anorectic active ingredient is selected from the group consisting of phentermine, phendimetrazine, diethylpropion, naltrexone, bupropion, and mixtures thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the appetite suppressant composition comprises each of a nutritive substance, a controlled drug delivery agent, and a cofactor, wherein the nutritive substance comprises a protein source.

### Claim 13 (depends on 12)

The method of claim 12, wherein the therapeutically effective amount comprises orally administering up to about 75 mg per day of phentermine.

### Claim 14 (depends on 12)

The method of claim 12, wherein the protein source comprises hydrolyzed powdered bovine or fish collagen, the controlled drug delivery agent comprises a cellulosic, and the cofactor comprises calcium picolinate, chromium picolinate, copper picolinate, magnesium picolinate, manganese picolinate, selenium picolinate, or zinc picolinate.

### Claim 15 (depends on 11)

The method of claim 11, wherein the appetite suppressant composition comprises each of a nutritive substance and a cofactor, and no controlled drug release agent, wherein the nutritive substance comprises a protein source.

### Claim 16 (depends on 15)

The method of claim 15, wherein the therapeutically effective amount comprises orally administering up to about 210 mg per day of phendimetrazine.

### Claim 17 (depends on 15)

The method of claim 15, wherein the therapeutically effective amount comprises orally administering up to about 150 mg per day of diethylpropion.

### Claim 18 (depends on 15)

The method of claim 15, wherein the protein source comprises hydrolyzed powdered bovine or fish collagen, and the cofactor comprises calcium picolinate, chromium picolinate, copper picolinate, magnesium picolinate, manganese picolinate, selenium picolinate, or zinc picolinate.

### Claim 19 (depends on 15)

The method of claim 15, wherein the cofactor is chromium picolinate.

### Claim 20 (depends on 11)

The method of claim 11, wherein the individual in need thereof is diagnosed overweight and obese.
